Related Experiment Video

Updated: Nov 18, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.2K

Recent advances of dual FGFR inhibitors as a novel therapy for cancer

Qi Liang1, Juelan Wang2, Liyun Zhao3

  • 1College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, 611756, China.

European Journal of Medicinal Chemistry
|February 8, 2021
PubMed

Insights

Dual fibroblast growth factor receptor (FGFR) inhibitors offer a promising strategy to overcome drug resistance in cancer therapy. This review explores recent advancements in dual FGFR inhibitors, highlighting their potential to enhance anti-cancer treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Fibroblast growth factor receptors (FGFRs) are crucial for normal biological processes but are implicated in various cancers.
  • Aberrant FGFR signaling contributes to tumorigenesis, progression, and resistance to anti-cancer therapies.
  • Current single-target FGFR inhibitors face challenges with acquired drug resistance.

Purpose of the Study:

  • To review recent research on dual FGFR inhibitors.
  • To discuss the potential of dual-target inhibition in overcoming drug resistance.
  • To provide commentary on the development of dual FGFR inhibitors.

Main Methods:

  • Literature review of recent studies on dual FGFR inhibitors.
  • Analysis of therapeutic strategies involving simultaneous inhibition of FGFR and other targets (e.g., VEGFR, EGFR, PI3K, CSF-1R).
  • Evaluation of challenges and advantages of dual-target inhibition.

Main Results:

  • Dual FGFR inhibitors represent a significant advancement in targeted cancer therapy.
  • Simultaneous inhibition of FGFR with other targets can enhance therapeutic effects.
  • Development of dual FGFR inhibitors aims to mitigate drug interactions associated with combination therapies.

Conclusions:

  • Dual FGFR inhibitors are a critical area of development for overcoming anti-cancer drug resistance.
  • Targeting FGFR in combination with other pathways offers enhanced efficacy.
  • Further research into dual FGFR inhibitors is essential for improved cancer treatment outcomes.
Keywords:
Acquired drug resistanceAnti-tumorDual inhibitorFGFR kinase

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

535
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K